Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

BACKGROUND: Lipid nanoparticle (LNP) encapsulated self-amplifying RNA (saRNA) is a novel technology formulated as a low dose vaccine against COVID-19. METHODS: A phase I first-in-human dose-ranging trial of a saRNA COVID-19 vaccine candidate LNP-nCoVsaRNA, was conducted at Imperial Clinical Research...

Descripción completa

Detalles Bibliográficos
Autores principales: Pollock, Katrina M., Cheeseman, Hannah M., Szubert, Alexander J., Libri, Vincenzo, Boffito, Marta, Owen, David, Bern, Henry, O'Hara, Jessica, McFarlane, Leon R., Lemm, Nana-Marie, McKay, Paul F., Rampling, Tommy, Yim, Yee Ting N., Milinkovic, Ana, Kingsley, Cherry, Cole, Tom, Fagerbrink, Susanne, Aban, Marites, Tanaka, Maniola, Mehdipour, Savviz, Robbins, Alexander, Budd, William, Faust, Saul N., Hassanin, Hana, Cosgrove, Catherine A., Winston, Alan, Fidler, Sarah, Dunn, David T., McCormack, Sheena, Shattock, Robin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759012/
https://www.ncbi.nlm.nih.gov/pubmed/35043093
http://dx.doi.org/10.1016/j.eclinm.2021.101262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759012/
https://www.ncbi.nlm.nih.gov/pubmed/35043093
http://dx.doi.org/10.1016/j.eclinm.2021.101262

Ejemplares similares